These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20726033)

  • 1. Pegylated interferon and ribavirin in real life: efficacy versus effectiveness.
    de Mattos AZ; de Almeida PR; Tovo CV; de Mattos AA
    Hepatology; 2010 Nov; 52(5):1867. PubMed ID: 20726033
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
    Jiménez-Méndez R; Castañeda-Hernández G
    Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
    Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
    Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
    [No Abstract]   [Full Text] [Related]  

  • 4. [Long-acting interferon: studies on pegylated interferon].
    Ma H; Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2002 Feb; 10(1):78-9. PubMed ID: 11856520
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful Hepatitis C Eradication With Preservation of Renal Function in a Liver/kidney Transplant Recipient Using Pegylated Interferon and Ribavirin.
    Mukherjee S; Ariyarantha K
    Transplantation; 2007 Nov; 84(10):1374-5. PubMed ID: 18049127
    [No Abstract]   [Full Text] [Related]  

  • 6. Pegylated interferon-alpha2a and ribavirin in HIV-hepatitis C coinfected patients.
    Expert Rev Anti Infect Ther; 2004 Jun; 2(3):341-2. PubMed ID: 15490503
    [No Abstract]   [Full Text] [Related]  

  • 7. Acquired factor VIII inhibitor in an HIV-infected patient after treatment with pegylated interferon-alpha 2a and ribavirin.
    Paul S; Javed U; Tevendale R; Lanford J; Liu R
    AIDS; 2007 Mar; 21(6):784-5. PubMed ID: 17413709
    [No Abstract]   [Full Text] [Related]  

  • 8. Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization.
    Foruny JR; Bárcena R; Moreno A; Blázquez J; Manzano R; Gil-Grande LA; Moreno A; Nuño J
    Transplantation; 2006 Jul; 82(2):289-90. PubMed ID: 16858295
    [No Abstract]   [Full Text] [Related]  

  • 9. Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?
    Hoefs JC; Morgan TR
    Hepatology; 2007 Dec; 46(6):1671-4. PubMed ID: 18046713
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients.
    Ridruejo E; Adrover R; Cocozzella D; Reggiardo MV; Fernández N
    Hepatology; 2010 Jun; 51(6):2231; author reply 2231-2. PubMed ID: 20513017
    [No Abstract]   [Full Text] [Related]  

  • 11. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
    Szalay F
    Orv Hetil; 2010 Feb; 151(7):271-3. PubMed ID: 20133247
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
    Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
    J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
    [No Abstract]   [Full Text] [Related]  

  • 13. PegIFN/ribavirin during acute HCV coinfection.
    Bernard EJ
    IAPAC Mon; 2004 Jul; 10(7):260-1. PubMed ID: 15624247
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of hepatitis C in children.
    Aziz S
    J Coll Physicians Surg Pak; 2005 Jun; 15(6):317-8. PubMed ID: 15924831
    [No Abstract]   [Full Text] [Related]  

  • 15. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.
    Medrano J; Barreiro P; Resino S; Tuma P; Rodríguez V; Vispo E; Labarga P; Madejón A; García-Samaniego J; Jiménez-Nácher I; Martín-Carbonero L; Soriano V
    Clin Infect Dis; 2009 Nov; 49(9):1397-401. PubMed ID: 19814621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C treatment, HAART and side effects.
    TreatmentUpdate; 2001; 13(7):7-8. PubMed ID: 11794865
    [No Abstract]   [Full Text] [Related]  

  • 17. Pegylated interferon-α2a versus pegylated interferon-α2b in hepatitis C: reappraisal of effectiveness on the basis of trial sequential analysis.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):246-8. PubMed ID: 24366456
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictors of response of U.S. veterans to treatment for the hepatitis C virus.
    Riley TR
    Hepatology; 2008 Jan; 47(1):356; author reply 356-7. PubMed ID: 18161713
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 20. Older age per se has negative effect on hepatitis C patients treated with peginterferon and ribavirin.
    Chen TM; Tung JN
    Am J Gastroenterol; 2009 Aug; 104(8):2117-9. PubMed ID: 19661945
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.